The objective of this randomized, double-blind, placebo-controlled study is to evaluate the effectiveness of Skal Pro in alleviating symptoms, enhancing stool consistency, improving quality of life, and addressing psychological distress in individuals diagnosed with irritable bowel syndrome (IBS), as compared to those who receive no intervention.
IBS diagnosed using the Rome IV criteria
Age above 18 years old and any gender
Any subtypes of IBS (diarrhea, constipation or mixed)
Presence of red flag symptoms (weight loss, anemia, night symptoms, abdominal mass, strong family history of cancer)
Was prescribed antibiotic (s) within the past one month
Medical conditions that contraindicate probiotic use including severe sepsis and pregnancy
Presence of bowel malignancy
EP Plus Group Sdn Bhd
Lead sponsor